Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | FGFR3 - TACC3 |
Gene Variant Detail | |
Relevant Treatment Approaches | FGFR Inhibitor (Pan) FGFR3 Inhibitor U0126 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 - CCDC6 FGFR3 - TACC3 | adrenal carcinoma | predicted - sensitive | Erdafitinib | Case Reports/Case Series | Actionable | In a Phase I trial, Balversa (erdafitinib) treatment resulted tumor shrinkage and no disease progression for 10 months in an adrenal carcinoma patient harboring FGFR3-TACC3 and FGFR2-CCDC6 fusions (PMID: 26324363; NCT01703481). | 26324363 |
FGFR3 - TACC3 FGFR3 over exp | urinary bladder cancer | sensitive | Futibatinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Futibatinib (TAS-120) treatment led to inhibition of cell proliferation in bladder cancer cell lines with FGFR3 overexpression and harboring FGFR3-TACC3 in culture, and led to inhibition of tumor growth in a cell line xenograft model (PMID: 32973082). | 32973082 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04424966 | Phase 0 | Infigratinib | Infigratinib in Recurrent High-Grade Glioma Patients | Recruiting | USA | 0 |